© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
October 03, 2022
Two recent clinical trials highlight the novel therapy options available to patients in the upfront and relapsed settings.
September 20, 2022
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.
April 20, 2022
Asciminib offers a new option for patients harboring the T315I mutation.
September 16, 2021
Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-based regimens.